Scientific References

Professional Systemic Support Poster References
Please use our Search feature to find pacific information about professional systemic enzyme support and conditions treated.

Professional Systemic Enzyme Support Poster References

[01] Gaciong Z., Lasek W., Jakobisiak M., Stoklosa T., Paczek L., Heidland A.. Therapy with proteolytic enzymes prolongs survival of mouse heart allografts. Inter. Journal of Tissue Reactions 1997, Vol. XIX, No.1/2, pp. 90 - 91, Abst. 110 - ISSN 0250-0868
[02] Gaciong Z., Paczek L., Bojakowski K., Wisniewski M., Lao M., Heidland A.. Treatment with proteolytic enzymes inhibits vascular allograft rejection in rats. Inter Journal of Tissue Reactions 1997, Vol. XIX, No.1/2, Abst. 120, pp. 96, ISSN 0250-0868 149K/245 (19-04-2).
[03] Heidland A., Sebekova K., Dämmrich J., Paczek L., Fierlbeck W., Krivosikova Z., Gaciong Z.. Malignant nephrosclerosis in Goldblatt hypertensive rats: amelioration by systemic enzyme therapy. Int J Tiss Reac Vol. XIX, No. 1/2, pp. 89 - 90, 1997 - abstract 109 SO 112 (19-04-2).
[04] Kabil S.M., Stauder G.. Oral enzyme therapy in hepatitis C patients. Int J Tiss Reac XIX (1/2), 1997 - abst. 122, pp. 97-98 - ISSN 0250-0868 149K/245 (19-04-2)
[05] Machanova M., Wald M., Prausova J., Bechyne M., Adamek J. Proteases - drug of the choice in the pharmacotherapy of lymphedema. 1 Oncology Department, Liberec Hospital, 2 Department of Surgery, 2nd Medical Faculty UK, Prague, 3 Oncology Department, Faculty Hospital Motol, Prague, 4 Dermatology Clinic, Faculty Hospital Bulovka, Prague. 2000
[06] Mertin J.1, Stauder G., and the ESEMS working group. Use of oral enzymes in multiple sclerosis patients. Inter. Journal of Tissue Reactions 1997, Vol. XIX , No.1/2, pp 95
[07] Navrátilová B., Navrátil L.. Use of systemic enzyme therapy in stomatology - current options (preliminary study). Miniinvazivní terapie 1998, číslo 3, str. 106-109 (16-13-1)
[08] Paczek L., Gaciong Z., Bartlomiejczyk I., Czyzyk A., Heidland A.. Beneficial effect of proteases on TGF-beta production in glomeruli from streptozotocin induced diabetes mellitus in rats. Inter. Journal of Tissue Reactions 1997, Vol. XIX, No. 1/2, pp 93, abstract 115, ISSN 0250-0868. 149K/245 (19-04-2)
[09] Sebeková K., Paczek L., Dämmrich J., Ling H., Schenk O., Gaciong Z., Spustová V., Heidland A.. Amelioration of the development of chronic renal failure by systemic enzyme treatment in the rat model of 5/6 nephrectomy. Inter. Journal of Tissue Reactions 1997, Vol. XIX, No. 1/2, pp 97 - abstract 121, ISSN 0250-0868. 149K/245 (19-04-2)
[10] Sebekova K, Paczek L, Dämmrich J, Ling H, Spustova V, Gaciong Z, and Heidland A. Effects of Protease Therapy in the Remnant Kidney model of Progressive Renal Failure. Mineral and Electrolyte Metabol. 1997: 23, pp 291-295. 344 KA (17-05-1).
[11] Stauder G., Donnerstag B., Baumhackl U., Buschmans E. Use of oral enzymes in multiple sclerosis: phenotyping of peripheral blood lymphocytes from MS patients under long-term treatment with orally administered hydrolytic enzymes. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp 135-137.
[12] Tarutinov V.I., Nosa P.P., Ros N.V., Galakhin K.A., Shpilevaja S.I. Systemic enzyme therapy in the complex treatment of breast cancer. Ukrainian Research Institute of Oncology and Radiobiology. 6th International Congress on Hormones and Cancer, September 5-9, 1999, Jerusalem, Israel
[13] Veldová Z., Martínková R., Maděrová S. Use of Phlogenzym^® in the treatment of secretory otitis in the outpatient practice. Audiocentrum Praha. 62. Congress of the Czech Society of Otorhinolaryngology and Surgery of Head and Neck, September 9-11, 1999, Hradec Králové, Czech Republic. (17-01-2)
[14] Vyhnánková L., Kabelka Z., Fišerová H., Lehovcová K., Groh D., Kopřivová H. Phlogenzym in the treatment of secretory otitis. ORL Clinic 2nd Medical Faculty and Faculty Hospital Motol, Czech Republic. 62. kongres České společnosti otorinolaryngologie a chirurgie hlavy a krku, 9.-11. září, 1999, Hradec Králové, abst. P 11
[15] Wald M., Pouèková P., Zadinová M., Olejár T. The effect of rectally administered proteinases in animal models of malignancies. International symposium of pediatric oncology, April 23 - 24, 1998, Prague, Czech Republic, abst. 33, pp. 50. 598 KA (19-03-3)
[16] Wiest-Ladenburger U.,¹ Richter W.,1 Moeller P.,² Boehm B. O.¹. Protease Treatment Delays Diabetes Onset in Diabetes-prone Nonobese Diabetic (NOD) Mice. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 75-78 - ISSN 0255-9625.
[16] Wiest-Ladenburger U.,¹ Richter W.,1 Moeller P.,² Boehm B. O.¹. Protease Treatment Delays Diabetes Onset in Diabetes-prone Nonobese Diabetic (NOD) Mice. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 75-78 - ISSN 0255-9625. Also: Inter. Journal of Tissue Reactions 1997, Vol. XIX, No. 1/2, abstract 108, pp. 89 - ISSN 0250-0868. SO 112 (4-12-2) (19-04-2)
[17] Emancipator S. N., Chintalacharuvu S. R., Urankar Nagy N., Petersilge C., Stauder G. Effects of Oral Enzymes in Collagen II Induced Arthritis in Mice. Int. J. Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 67-74 - ISSN 0255-9625 SO 112 (3-11-1) (19-04-2)
[18] Kerkhoffs GM, Struijs PA, de Wit C, Rahlfs VW, Zwipp H, van Dijk CN. A double blind, randomised, parallel group study on the efficacy and safety of treating acute lateral ankle sprain with oral hydrolytic enzymes. Br J Sports Med. 2004 Aug;38(4):431-5.
[19] Klein G., Kullich W. Pain Reduction in Rheumatic Diseases by Oral Therapy with Enzymes. Wien. Med. Wschr. 1999, 149, pp. 577-580.
[20] Klein G, Kullich W, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2006 Jan-Feb;24(1):25-30.
[21] Kleine M.W. Evidence of the efficacy of an enzyme combination preparation using the method of artificial hematomas in combination with a pressure meter: A placebo controlled, randomised, prospective, double blind study. Journal of Clinical Research 1998, Vol.1, pp. 87-102. PZ 12 (16-08-1). Allergist / Phlebologist / Sports Medicine, Egenhofenstrasse 18, D-82152. Planegg, Germany.
[22] Levenets V.N. , LopuschanV.M., Protsenko G. Systemic enzyme therapy in orthopedics and traumatology. Klinitschna khirurgia 1997, 9-10, p. 50
[23] Mazourov V.I., Lila A.M., Klimko N.N., Raimue K.V., Makulova T.G. The role of systemic enzymotherapy in the treatment of rheumatoid arthritis. Reumatologia 1998, Suppl Vol. XXXVI, Warsaw 1998, Lectures No. 211, pp 108-110 ISSN 0034-6233. 619 KA (19-09-2).
[24] Mazurov V.I., Lila A.M. Optimization of reactive arthritis treatment using systemic enzyme therapy. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 125-128 - ISSN 0255-9625. 218 K/375 (19-05-3)
[25] MU-91410. Primary Investigator: Dr. med. Marcel Baumüller. Phlogenzym® in patients with lateral ankle joint distortions. Efficacy and the tolerance. Study Nr.: MU-91410. Randomised double blind clinical trial with two parallel groups against Placebo.
[26] MU-91411. Principal Investigator: Rahn Hans-Dieter, M.D. Enzyme Therapy with Wobenzym® or Phlogenzym® in Ankle Joint Distortion. Efficacy and Tolerability. Study-No.: MU-91411. Three-armed randomized double-blind parallel group study vs. Placebo.
[27] MU-692402. Principal Investigator: Hans-Martin Fritsche, M.D., Oberarzt. Phlogenzym^® as a Pre- and Postoperative Anti-Edematous Therapy in Patients with Surgery for an Implantation of an Artificial Knee Joint. Efficacy and Tolerance. Study No.: MU-692402. Clinical Study Report. Double-blind randomized clinical trial phase III with parallel groups versus diclofenac.
[28] MU-695414. Primary Investigator: Univ.-Doc. Franz Singer, M.D. Phlogenzym® in the Treatment of a Monoarticular Gonarthritis. Efficacy and Tolerance. MU-695414 Randomised double-blind, clinical study phase III with parallel groups vs. diclofenac according to the guidelines of good clinical practice (GCP). Integrated biometric-medical report according to ICH E3 guidelines.
[29] MU-695419. Primary Investigator: Prim. Univ.-Prof. Gert Klein, M.D. Phlogenzym® in the Treatment of Periarthritis Humeroscapularis Tendopathica.Randomised double-blind study phase III with parallel groups vs. diclofenac according to the guidelines of good clinical practice (GCP) Study No.: MU-695419. Efficacy and Tolerance. Integrated biometric-medical final report according to ICH E3 guidelines
[30] MU-696401. Primary Investigator: Univ.-Prof. Gert Klein, M.D. Phlogenzym® in the Treatment of a Monoarticular Gonarthritis (MU-696401) Efficacy and Tolerance. Randomised double-blind study phase III with parallel groups vs. diclofenac according to the guidelines of good clinical practice (GCP). Integrated final report according to ICH E3 guidelines
[31] MU-696416. Herrera E.G. Phlogenzym in the treatment of a monoarticular painful gonarthritis. Efficacy and tolerance. Hospital Aragon Avenida 506 entre Calle 521 y 519, Unidad San Juan de Aragon, Delegacion Gustavo A. Madero, Mexico D.F., C.P. 0792. Randomized double-blind study with parallel groups vs. diclofenac. Study Period: January 1997 - May 1997. Study No.: MU-696416
[32] Singer F., Singer C., Oberleitner H. Phlogenzym^® versus Diclofenac in the treatment of activated osteoarthritis of the knee. A double-blind prospective randomized study. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 135-141- ISSN 0255-9625. 218 K/375 (19-05-3)
[33] Wittenborga A., Bockb P. R., Hanischb J., Sailerc R., and Schneiderd B. Comparative Epidemiological Study in Patients with Rheumatic Diseases Illustrated in an Example of a Treatment with Non-Steroidal Anti-inflammatory Drugs versus an Oral Enzyme Combination. Arzneimittel-Forschung/Drug Research 2000, Vol. 50 (II), No. 8, pp. 728-738. PZ 20 (3-14-2)
[34] Kamenícek V, Holán P, Franĕk P. Systemic enzyme therapy in the treatment and prevention of post-traumatic and postoperative swelling. Acta Chir Orthop Traumatol Cech. 2001;68(1):45-49.
[35] Kopadze, T.Sh., Natsvlishvili, G.A., Tvaladze, M.G., Avazashvili, D.N. Application of Wobenzym and Phlogenzym to the angiology and vascular surgery. Abstract in Russian. Georgian Medical News 2001, No. 2, (serial No.71), pp. 27 – 29.
[36] Pluzhnikov M. S., Ryabova M.A., Karpiscenko S.A. The effect of systemic enzyme therapy (Phlogenzym) in the treatment of radiomucositis in patients with laryngeal cancer. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae 1999, Vol. 5, No.1-2/99, pp. 73-75. 17 KR
[37] Kamenícek, V., Holan; P. . Systemic enzyme therapy in osteosyntheses of the long bones. Rozhledy v Chirurgii 1999, Jun; 78(6): 279-281. Artilce in Czech.
[38] Klein G., Singer F., Herrera E.G. Phlogenzym in the treatment of monoarticular gonarthritis. A meta-analysis of three studies comparing efficacy and tolerance of Phlogenzym with that of Diclofenac in patients with monoarticular gonarthritis. December 2, 1998
[39] Koshkin V.M., Kirienko A.I., Leontjev S.G., Agafonov V.F. Systemic enzyme therapy of lower limb postphlebitic syndrome. Angiology and vascular surgery 2000, Vol. 6, No. 2, pp. 61 – 64.
[40] Saradeth T., Quittan M., Ghanem A. H., Ernst E. Improvement in blood fluidity characteristics via Phlogenzym -An in vitro pilot study. Perfusion 1995: Jahrgang 8, Nr. 6, pp. 196-198. PZ 4 (17-06-2)
[41] Koshkin V.M., Kirienko A.I. Systemic enzyme therapy in the treatment of acute thrombosis of superficial veins in the lower extremities and postthrombophlebitic disease. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 121-124 - ISSN 0255-9625. 218 K/375 (17-10-2)-(19-05-3)
[42] MU-697411. Šebeková K.1, Heidland A.2 , Krivošíková Z., Daemmrich J. The effect of intraperitoneal administration of Phlogenzym on the development of accelerated glomerulosclerosis in Goldblatt hypertensive rats. Study No.:MU-697411. 1 Clinic of Pharmcotherapy, Institute of Preventive and Clinical Medicine Bratislava, Slovakia. 2 Medizinische Klini, University of Wuerzburg, Wuerzburg, Germany.
[43] ŠebekováK., Dämmrich J., Krivošíková Z., Heidland A. The effect of oral protease administration in the rat remnant kidney model. Research in Experimental Medicine 1999, Vol. 199, No. 3, December 1999, pp. 177-188-(A20511). PZ 16 (5-09-2)
[44] Targoni O.S., Tary-Lehmann M. and Lehmann P.V. Prevention of Murine EAE by Oral Hydrolytic Enzyme Treatment. Journal of Autoimmunity 1999, Vol. 12, pp. 191-198, PZ 14 (18-02-3)
[45] BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Chang A., Scheer M., Grote A., Schomburg I., Schomburg D. Nucleic Acids Res. 2009, Vol. 37, Database issue, D588-D592. http://www.brenda-enzymes.org
[46] RCSB Protein Data Bank. http://www.rcsb.org
[47] Wald, et al. Systemic Enzyme Support: an Overview. NutriNews. 600 Boyce Road • Pittsburgh, PA 15205 August, 2008. http://douglaslabs.com/pdf/nutrinews/Systemic%20Enzyme%20Support%20NN%20%2808-08%29.pdf
[48] J. F. Couch, J. Naghski, C. F. Krewson. Rutin Content of Sophora japonica L. J. Am. Chem. Soc., 1952, 74 (2), pp 424–425. http://pubs.acs.org/doi/abs/10.1021/ja01122a042
[49] PubChem. CID 16218542 http://pubchem.ncbi.nlm.nih.gov/
[50] Borth, W. Alpha 2-macroglobulin: a multifunctional binding protein with targeting characteristics. The FASEB Journal, Vol 6, 3345-3353. http://www.ncbi.nlm.nih.gov/pubmed/1281457
[51] Gonias SL, Pizzo SV. Conformation and protease binding activity of binary and tertiary human alpha 2-macroglobulin-protease complexes. J Biol Chem. 1983 Dec 10;258(23):14682-5.
[52] Mettenburg JM, Gonias SL. Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes. Protein J. 2005 Feb;24(2):89-93.
[53] LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991 Jul;65(1):3-14.
[54] French K, Yerbury JJ, Wilson MR. Protease activation of alpha2-macroglobulin modulates a
chaperone-like action with broad specificity. Biochemistry. 2008 Jan 29;47(4):1176-85.
[55] Lauer D, Reichenbach A, Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1--42: a mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001 Feb;167(2):385-92.
[56] Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ. Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem. 1996 Apr 5;271(14):8443-51.
[57] Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM. alpha2-Macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997 Jul;69(1):299-305.
[58] Hughes SR, Khorkova O, Goyal S, Knaeblein J, Heroux J, Riedel NG, Sahasrabudhe S. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3275-80.
[59] Mettenburg JM, Gonias SL. Beta-amyloid peptide binds equivalently to binary and ternary alpha2-macroglobulin-protease complexes. Protein J. 2005 Feb;24(2):89-93.
[60] Qiu Z, Strickland DK, Hyman BT, Rebeck GW. Alpha2-macroglobulin enhances the clearance of endogenous soluble beta-amyloid peptide via low-density lipoprotein receptor-related protein in cortical neurons. J Neurochem. 1999 Oct;73(4):1393-8.
[61] Stvrtinova V, Jakubovky J, Hulin I. Inflammation and Fever. From: Pathophysiology Principls of Disease. 1.4 Mediators of Inflammation. 1995 Academic Electronic Press. http://nic.sav.sk/logos/books/scientific/ SBN 80--967366--1--2
[62] Sizyakina L.P., Efremov V.V. Efficiency of system enzyme therapy in immunopathological states. International Journal on Immunorehabilitation 2001, 3, 2, 75.
[63] Vokálová I. Systemic enzyme therapy in the treatment of children with recurrent infections of respiratory tract. VOX PEDIATRIAE 2003, Vol. 2., No. 9, pp. 29 – 30. [Czech]
[64] Rowland FN, Donovan MJ, Gillies C, O'Rourke J, Kreutzer DL. Fibrin: mediator of in vivo and in vitro injury and inflammation. Curr Eye Res. 1985 May;4(5):537-53. http://www.ncbi.nlm.nih.gov/pubmed/3874755
[65] Zaciragic A, Lepara O, Valjevac A, Arslanagic S, Fajkic A, Hadzovic-Dzuvo A, Avdagic N, Alajbegovic A, Mehmedika-Suljic E, Coric G. Elevated serum C-reactive protein concentration in Bosnian patients with probable Alzheimer's disease. J Alzheimers Dis. 2007 Sep;12(2):151-6. http://www.ncbi.nlm.nih.gov/pubmed/17917159
[66] Misra UK, Sharma T, Pizzo SV. Ligation of cell surface-associated glucose-regulated protein 78 by receptor-recognized forms of alpha 2-macroglobulin:activation of p21-activated protein kinase-2-dependent signaling in murine peritoneal macrophages. J Immunol. 2005 Aug 15;175(4):2525-33.
[67] Feldman SR, Ney KA, Gonias SL, Pizzo SV. In vitro binding and in vivo clearance of human alpha 2-macroglobulin after reaction with endoproteases from four different classes. Biochem Biophys Res Commun. 1983 Jul 29;114(2):757-62.
[68] Mazourov V.I., Lila A.M., Klimko N.N., Raimuev K.V, Makulova T.G. The Efficacy of Systemic Enzyme Therapy in the Treatment of Rheumatoid Arthritis. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 85-91.
[69] Mazurov V.I., Stolov S.V., Linetskaya N.E., Onyschenko E.F. Systemic enzyme therapy in the complex treatment of angina pectoris. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 113-120.
[70] Lauer D., Müller R., Cott C., Otto A., Naumann M., Birkenmeier G. Modulation of growth factor binding properties of a2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol 2001, Vol. 47., Suppl. July 2001, S 4 – 9. 519 KA (2-13-2)-(20-00-2).
[71] MU-694422. Primary Investigators: Peter Schlüter, M.D. Phlogenzym^® in the Treatment of Chronic Prostatitis. Efficacy and Tolerance. Study No.: MU-694422. Randomised double-blind study phase III with parallel groups vs. placebo according to the guidelines of good clinical practice (GCP).
[72] Schlüter P. Efficacy and tolerance of oral enzyme therapy in chronic prostatitis: Results of a double-blind therapy study. European Journal for Infectious and Immunological Diseases 1998, Vol. 2, pp. 57-69
[73] Klein G. and Kullich W.. Short-Term Treatment of Painful Osteoarthritis of the Knee with Oral Enzymes. A Randomised, Double-Blind Study versus Diclofenac. Clinical Drug Investigation, 2000, Vol. 19, No. 1, pp. 15-23 - ISSN 1173-2563. PZ 18 (4-03-1)

[74] Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W. Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial. J Assoc Physicians India. 2001 Jun;49:617-21.
[75] Kullich W., Klein G.. Treatment with oral enzymes in painful osteoarthritis of the knee and periarthritis of the shoulder. Reumatologia 1998, Suppl Vol. XXXVI, Warsaw 1998, Lectures No. 213, pp 111-114. ISSN 0034-6233. 619 KA (19-09-2)
[76] MU-693405. Pavelka K. Efficacy and safety of an oral hydrolytic enzyme therapy in patients with rheumatoid arthritis. Institute of Rheumatology, Prague, Czech Republic. The clinical study report. Study No.: MU-693405.
[77] Hanisch J. Phlogenzym® in activated, inflammatory - degenerative spinal and joint diseases, fibromyalgias and other rheumatic soft - tissue diseases. A reference - controlled, multicentric, retrospective analysis of therapeutical data Summary and comments on the project. IFAG Basel, November 1995
[78] Dosenko V.E., Zakharova V.P., Byc Y.V. The systemic enzyme therapy in experimental atherosclerosis. Experimental cardiology 2000, No. 5-6, pp. 87-94.
[79] Sledzevskaya I.K., Loboda M.V., Kolesnik E.A., Babiy L.N., Fisenko L.I. Systemic enzyme treatment as a method of secondary prevention in patients after myocardial infarction in the rehabilitation period. II Mediterranean Congress of Physical Medicine and Rehabilitation, 20-23 May, 1998, Valencia, Spain. Abstracts- pp. 137 489 KA (19-08-3).
[80] Sledzevskaja U. K., Šumakov V. A., Bratus V. B., Babij A., Malinovskaja U. Z., Gavrilenko T. U., Terzov A. U. Systemic enzyme therapy in the treatment of patients with myocardial infarction. Žurnal praktièeskogo vraèa 1997, No. 3, pp. 43 – 44.
[81] Kovalenko V.N., Sledzevskaya I.K., Ryabokon E.N., Gavrilenko T.I., Terzov A.I. N.D. Strazhesko New approaches to modern cardiology based on systemic enzyme therapy. Int. J. Immunotherapy 2001, Vol. XVII, No. 2/3/4, pp. 101-111.
[82] Stauder G., Wood G., Paczek L. Enzyme Therapy in Diabetic Nephropathy – Experimental and First Clinical Data. Czech summary. 6th Taormina Course of Nephrology. October 20th - 22th, 2000, pp. 227-232, Editoriale Bios 2000 PZ 22 (5-14-3)-(19-11-3).
[83] Stauder G., Kabil S2. Oral enzyme therapy in hepatitis C patients. Inter. Journal of Immunotherapy 1997, Vol. XIII, No. 3/4, pp 153-158, ISSN 0255-9625. SO 112 (19-04-2) - (4-12-1)
[84] Shahid S.K. Turakhia N.H. Kundra M. , Shanbag P. , Daftary G.V.² Schiess W.. Efficacy and safety of Phlogenzym - a protease formulation, in sepsis in children. J Assoc Physicians India (JAPI) 2002, Vol. 50, pp. 527-531.
[85] Wald M.¹, Køížová H.². Diagnosis of an early (latent) stage of secondary lymphedema of the arm - a necessary condition for its successful treatment. Przeglad lekarski 2000, Vol. 57 Suppl.5/2000, pøednáška 56, pp. 116 - ISSN 0033-2240. 510 KA (19-13-3)-(2-12-2)
[86] Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov S.A. Immunological aspects of systemic enzyme therapy (SET) in the complex treatment of recurrent nephrolithiasis. 1st National Congress of the Ukraine on Immunology, Allergology, and Immunorehabilitation. Odessa State Medical University.
[87] Borisov O.V. Coenzyme metabolic assurance of patients with recurrent nephrolithiasis in the complex treatment by systemic enzyme therapy. Urologia 1998, 3, pp. 29-35. Odessa Medical University, Department of Urology, Odessa, Ukraine
[88] Sebekova K., Daemmrich J., Paczek L., Gaciong Z., Blazicek P., Spustova V. Heidland A.. Amelioration of the progressive course of chronic renal failure in subtotally nephrectomized rats by intraperitoneal enzyme therapy. Nieren- und Hochdruckkrankheiten 1997, Jahr. 26, No. 6/1997, s. 277-281. 345 KA (5-08-1)
[89] Emancipator S.N., Chintalacharuvu S.R., Urankar Nagy N., Stauder G.. Oral Enzymes in Different Animal Models of Glomerulonephritis. Int J. Immunotherapy 1997, Vol. XIII, No. 3/4, pp. 97-103 - ISSN 0255-9625 SO 112 (19-04-2)- (5-07-2)
[90] Sebekova K., Fierlbeck W., Krivosikova Z., Schinzel R., Dämmrich J., Galbavy S., Blazicek P., Syrova D., Heidland A. Proteolytic enzymes in attenuation of tubulointerstitial fibrosis in various models of non-immune mediated renal disease. Biomedical subedition Folia Medica Cassoviensia 1999, č. 5 - Transactions of the Universities of Košice
[91] Rovenská E., Švík K., Stanèíková M., Rovenský J. Enzyme and combination therapy with cyclosporin A in the rat developing adjuvant arthritis. Int. J. Tissue React. 1999, Vol. XXI, No. 4, pp. 105-111 - ISSN 0250-0868. 626 KA (3-11-2)
[92] Kovalenko V.N., Protsenko G.A., Carenok M.N. Osteoarthrosis: theory and practice of conservative treatment. Medical Practice 1998: 1, 12-14. Research Institute of Cardiology, Kiev, Ukraine
[93] Stauder G. Oral enzyme therapy in the animal model of collagen-II induced arthritis in mice. Reumatologia 1998, Suppl Vol. XXXVI, Warsaw 1998, Lectures No. 210, pp 106-107. ISSN 0034-6233. 619 KA (19-09-2)
[94] Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol. 2001 Jul;47 Suppl:S10-5.
[95] Porubská M. Our first experience with utilisation of hydrolytic enzymes in arterior uveitis. Rheumatologia 2000, Roč. 14, č. 2, str. 65-69. (3-14-1).
[96] MU-697403. Primary Investigator: Michael-W. Kleine M. D, Egenhofenstrasse 18, D-82152 Planegg, Germany. Phlogenzym® in the Model of an Experimentally Induced Hematoma. Dose-Response Study. Study No.: MU-697403. Randomised double-blind study phase II with four parallel dosing groups including placebo according to the guidelines of good clinical practice (GOP). Integrated biometric-medical final report according to ICH E3 guidelines
[97] MU-91416. Principal investigator: Michael-W. Kleine, M.D. Reduction of tenderness and hematoma by Phlogenzym® in volunteers with an experimental hematoma. Efficacy and tolerance. Study No: MU-91416. Double-blind randomized experimental clinical parallel group study versus placebo.
[98] MU-692423. Principal Investigator: Hanns-Dietrich Rahn, M.D. Oral Enzyme Therapy in the Treatment of Ankle Joint Distortions (MU-692423). Efficacy and Safety. Study No.: MU-692423. Randomised, double-blind, controlled clinical trial with two parallel groups Phlogenzym^® vs. enzyme preparation without rutoside.
[99] Lukáš, J., Hrobon, M., Kana,R. Phlogenzym, systemic enzymotherapy in septoplasty. Choroby hlavy a krku (Head and Neck Diseases), 2000, 1/2000, str. 7-9. (17-00-3)
[100] Švík K., Rovenská E., Stanèíková M., Rovenský J. The effect of enzyme therapy and natrium alendronan on ovariectomized female rats. The Research Institute of Rheumatic Diseases, Piešany, SR. 3. Kongres slovenských a èeských osteológov + IOF 2000, Banská Bystrica, 7.-9. sept., poster str. 48
[101] MU-692411. Primary Investigator: Dr. med. Peter Schlüter. Phlogenzym® in patients with relapsing urinary tract infections. Efficacy and tolerance. Study Nr.: MU-692411. Randomized double blind clinical phase III (acc. to German drug law) trial with two paralIel groups against Placebo.
[102] MU-695416. Prof. Dr. med. J. Sökeland, Dortmund, Germany. Enzyme Therapy of Patients with Acute Hemorrhagic Cystitis. MU-695416 Randomized, Placebo controlled, Clinical, Double-blind, Multicenter Study of Phase III According to the European Standard of Good Clinical Practice (GCP).

SYSTEMIC ENZYME SUPPORT.org

Scientific References